Last reviewed 2026-04-20 · How we verify

VUEWAY

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Vueway is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of t

Common side effects

• Injection site pain
• Headache
• Nausea
• Injection site warmth
• Injection site coldness
• Dizziness
• Localized swelling
• Erythema
• Maculopapular rash
• Vomiting
• Feeling hot
• Pyrexia

Serious adverse events

• Nephrogenic Systemic Fibrosis
• Acute pancreatitis
• Acute respiratory distress syndrome
• Pulmonary edema
• Hypersensitivity Reactions
• Worsened renal impairment
• Gadolinium-associated plaques
• Cystatin C increase
• Blood creatinine increase

Key clinical trials

• Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease (NA)
• Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings (PHASE4)
• Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VUEWAY CI brief — competitive landscape report
• VUEWAY updates RSS · CI watch RSS
• M.D. Anderson Cancer Center portfolio CI